Design Therapeutics Operating Cash Flow Growth & History (DSGN)
Design Therapeutics's operating cash flow was −$54.4M for fiscal 2025.
View full Design Therapeutics company overviewDesign Therapeutics annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$54.4M | −$11.3M | — |
| 2024 | 2024-12-31 | −$43.1M | $15.5M | — |
| 2023 | 2023-12-31 | −$58.6M | −$7.2M | — |
| 2022 | 2022-12-31 | −$51.3M | −$21.9M | — |
| 2021 | 2021-12-31 | −$29.4M | −$20.7M | — |
| 2020 | 2020-12-31 | −$8.7M | — | — |
Design Therapeutics quarterly operating cash flow
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$15.5M | −$1.1M | — |
| Q1 2026 | 2026-03-31 | −$16.4M | $358,000 | — |
| Q4 2025 | 2025-12-31 | −$12.0M | −$2.1M | — |
| Q3 2025 | 2025-09-30 | −$11.2M | −$1.6M | — |
| Q2 2025 | 2025-06-30 | −$14.4M | −$3.2M | — |
| Q1 2025 | 2025-03-31 | −$16.8M | −$4.3M | — |
| Q4 2024 | 2024-12-31 | −$9.9M | $2.9M | — |
| Q3 2024 | 2024-09-30 | −$9.5M | $5.0M | — |
| Q2 2024 | 2024-06-30 | −$11.3M | $2.5M | — |
| Q1 2024 | 2024-03-31 | −$12.4M | $5.0M | — |
| Q4 2023 | 2023-12-31 | −$12.8M | $2.3M | — |
| Q3 2023 | 2023-09-30 | −$14.5M | −$635,000 | — |
| Q2 2023 | 2023-06-30 | −$13.8M | −$3.3M | — |
| Q1 2023 | 2023-03-31 | −$17.4M | −$5.6M | — |
| Q4 2022 | 2022-12-31 | −$15.1M | −$5.9M | — |
| Q3 2022 | 2022-09-30 | −$13.9M | −$5.7M | — |
| Q2 2022 | 2022-06-30 | −$10.5M | −$2.2M | — |
| Q1 2022 | 2022-03-31 | −$11.8M | −$8.1M | — |
| Q4 2021 | 2021-12-31 | −$9.2M | −$6.4M | — |
| Q3 2021 | 2021-09-30 | −$8.2M | −$6.3M | — |
| Q2 2021 | 2021-06-30 | −$8.3M | −$7.0M | — |
| Q1 2021 | 2021-03-31 | −$3.7M | −$1.0M | — |
| Q4 2020 | 2020-12-31 | −$2.8M | — | — |
| Q3 2020 | 2020-09-30 | −$1.9M | — | — |
| Q2 2020 | 2020-06-30 | −$1.3M | — | — |
| Q1 2020 | 2020-03-31 | −$2.7M | — | — |
Design Therapeutics operating cash flow trends
Over the last five fiscal years, Design Therapeutics's operating cash flow decreased from −$8.7M to −$54.4M, a change of −$45.7M. The latest reported quarter, Q2 2026, shows −$15.5M.
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Design Therapeutics source filings ↗